Haemonetics Number Of Shares Shorted vs. Net Income

HAE Stock

USD 60.05 0.35 0.59%

Based on Haemonetics' profitability indicators, Haemonetics is yielding more profit at this time than in the previous quarter. Current readings indicate it has a moderate probability of reporting better profitability numbers in April. Profitability indicators assess Haemonetics' ability to earn profits and add value for shareholders.Based on recent performance metrics, Sales General And Administrative To Revenue is expected to increase slightly. Year-ago financials show Haemonetics with Sales General And Administrative To Revenue of 0.32. As of now, The current year's Days Of Sales Outstanding is projected to rise to 77.02, whereas EV To Sales is moving lower toward 2.23. Comparative financial data indicate that Net Income is shifting by roughly 4.76%. Year-ago financials show Haemonetics with Net Income of 192.83 Million. As of now, The current year's Income Before Tax is projected to rise to approximately 256.1 M, whereas Total Other Income Expense Net is moving lower toward about -11.8 M. Pretax Profit Margin is evolving in line with broader financial reporting trends. Year-ago financials show Haemonetics with Pretax Profit Margin of 0.12. As of now, The current year's Operating Profit Margin is projected to rise to 0.13, whereas Net Profit Margin is moving lower toward 0.08.

Current Value

Last Year

Change From Last Year

10 Year Trend

Gross Profit Margin

0.57

0.5438

Sufficiently Up

Slightly volatile

Net Profit Margin

0.0834

0.0898

Significantly Down

Slightly volatile

Operating Profit Margin

0.13

0.126

Sufficiently Up

Slightly volatile

Pretax Profit Margin

0.12

0.116

Sufficiently Up

Slightly volatile

Return On Assets

0.0694

0.0535

Significantly Up

Slightly volatile

Return On Equity

0.11

0.1225

Moderately Down

Slightly volatile

Profitability context for Haemonetics is derived from margins and returns tied to revenue, assets, and operating expenses.

Build portfolio with Haemonetics Stock

Revenue by Earning Segment

Haemonetics generates revenue across 6 reported product segments. The largest contributor is Hospital at 143.5 Million (26.6% of revenue), with Plasma accounting for 138.91 Million (25.8%). Haemonetics' revenue is spread relatively evenly across product segments, reducing single-segment risk.

Risk vs Return Analysis.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Projected EPS for Haemonetics is 1.27, with a low-high corridor of 1.23 to 1.25. The latest trailing EPS is 3.62, allowing a direct check of consensus level versus realized earnings base. Consensus EPS estimates for Haemonetics typically reference EPS before non-recurring items. These estimates can include stock-based compensation expense.

Macro event markers

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Haemonetics is projected to report an EPS estimate of 1.27 on 31st of March 2026. Analyst consensus for Haemonetics is presented with historical volatility context..

Haemonetics Revenue by Earnings Segment Overview

This chart illustrates Haemonetics' revenue composition by product line based on the latest available data. The smallest reported segment is Interventional Technologies, Hospital at 10.4% of total revenue.

The estimates help frame performance context across reporting periods. The estimates are presented as context for broader analysis and timeframe comparison.

Quarterly Earnings Growth

0.284

Earnings Share

3.62

Revenue Per Share

27.509

Quarterly Revenue Growth

-0.03

Return On Assets

0.0645

Haemonetics's market price can diverge from book value, the accounting figure shown on Haemonetics's balance sheet. Haemonetics' market capitalization is 2.79 B. The 3.06 P/B ratio shows Haemonetics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 3.65 B. Value and price for Haemonetics are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.

Note that Haemonetics' intrinsic value and market price are different measures derived from different inputs. For Haemonetics, key inputs include a P/E ratio of 50.35, a P/B ratio of 3.06, a profit margin of 13.31%, and ROE of 19.3%. Where Haemonetics trades at any moment depends on the balance of buying and selling pressure.

Haemonetics Net Income vs. Number Of Shares Shorted Fundamental Analysis

Comparative market metrics assess Haemonetics's pricing relative to peers.

Haemonetics is rated below average for number of shares shorted relative to top peers. It holds the #2 position for net income relative to top peers with a Net Income-to-Number Of Shares Shorted ratio near 61.88 . Comparative financial data indicate that Net Income is shifting by roughly 4.76%. Year-ago financials show Haemonetics with Net Income of 192.83 Million. Valuation multiples such as P/E, P/B, and P/S compare Haemonetics to peer earnings performance.

Haemonetics Net Income vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Haemonetics

Shares Shorted

by Public

+

by Institutions

2.71 M

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Haemonetics

Net Income

(Rev + Gain)

-

(Exp + Loss)

167.68 M

Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Haemonetics Net Income Comparison

Haemonetics is currently under evaluation for net income relative to top peers.

Haemonetics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Haemonetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Haemonetics will eventually generate negative long term returns. The profitability progress is the general direction of Haemonetics' change in net profit over the period of time. It can combine multiple indicators of Haemonetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.

	Last Reported	Projected for Next Year
Accumulated Other Comprehensive Income	-63.3 M	-60.2 M
Operating Income	255.1 M	267.8 M
Total Other Income Expense Net	-11.2 M	-11.8 M
Net Income	192.8 M	202.5 M
Income Before Tax	243.9 M	256.1 M
Income Tax Expense	51.1 M	53.6 M
Net Income Applicable To Common Shares	192.8 M	202.5 M
Net Income From Continuing Ops	192.8 M	202.5 M
Non Operating Income Net Other	-13.2 M	-13.8 M
Interest Income	11.2 M	13.2 M
Net Interest Income	-8.8 M	-9.2 M
Change To Netincome	41.6 M	40.4 M
Net Income Per Share	2.32	2.43
Income Quality	1.55	1.47
Net Income Per E B T	0.77	0.44

Haemonetics Profitability Driver Comparison

Profitability drivers are factors that directly affect the investment outlook for Haemonetics. Investors recognize that outcomes may not unfold as predicted, because unforeseen events and market disruptions can arise at any point and significantly alter the earnings trajectory.

Earnings Estimation Breakdown

The calculation of Haemonetics' earnings per share is based on data from the past 12 consecutive months used for reporting the company's financial figures. The next projected EPS of Haemonetics is estimated to be 1.27 with the future projection ranging from a low of 1.2325 to a high of 1.245. Please be aware that this consensus of annual earnings estimates for Haemonetics is based on EPS before non-recurring items.

Last Reported EPS

0.95

1.23

Lowest

Expected EPS

1.27

1.25

Highest

Earnings Projection Consensus

A consensus EPS-based estimate above Haemonetics' current price may suggest the market is pricing in excessive pessimism or overlooking near-term catalysts. Conversely, an estimate below market price could reflect a premium valuation that requires sustained earnings growth to justify. Both interpretations demand risk assessment and should not be acted upon in isolation.

Number of Analysts	Historical Accuracy	Last Reported EPS		Estimated EPS for 31st of March 2026	Current EPS (TTM)
11	91.39%	0.95		1.27	3.62

Earnings History

Earnings estimate consensus by Haemonetics analysts from Wall Street is used by the market to judge Haemonetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we suggest analyzing not only Haemonetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Haemonetics Quarterly Gross Profit

191.41 Million

Based on recent performance metrics, Earnings Yield are expected to slightly decrease. A year ago, Earnings Yield were sitting at 0.03. As of now, The current year's Price Earnings To Growth Ratio is projected to rise to 17.43, whereas Retained Earnings are moving lower toward about 285 M. As of now, The current year's Net Income Applicable To Common Shares is projected to rise to approximately 202.5 M, whereas Common Stock Shares Outstanding is moving lower toward about 42.5 M.

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Haemonetics' price to converge to an average value over time is called mean reversion.

Hype

Prediction

Low	Estimated	High
58.04	60.05	62.06

Details

Intrinsic

Valuation

Low	Real	High
52.93	54.94	66.06

Details

Naive

Forecast

Low	Next	High
52.02	54.03	56.04

Details

Analyst

Consensus

Low	Target	High
79.63	87.50	97.13

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Haemonetics. Your research has to be compared to or analyzed against Haemonetics' peers to derive any actionable benefits. Major investment banks and asset managers with significant Haemonetics exposure routinely update their models around earnings events. Their collective positioning and reaction to consensus deviations often define the immediate post-earnings trend. For short-term traders, this institutional sensitivity to consensus makes the EPS surprise the single most watched event variable.

Earnings per Share Projection vs Actual

When Haemonetics reports actual EPS, investors compare it against the analyst consensus estimate for Haemonetics to judge performance. A beat versus consensus is typically interpreted as positive execution; a miss signals a shortfall relative to expectations. EPS is expressed on a weighted average per-share basis to account for equity changes within the reporting period.

Estimated Months Earnings per Share

EPS serves income investors in Haemonetics as a quick gauge of dividend affordability: the higher the EPS relative to the dividend per share, the more cushion management has. However, accounting EPS can diverge from cash-based earnings, so investors should validate EPS signals with operating cash flow and capex data. Comparing Haemonetics' EPS to sector peers provides further context for dividend sustainability.

Quarterly Analyst Estimates and Surprise Metrics

Earnings surprise history for Haemonetics' reveals whether the company tends to guide conservatively or struggles to meet analyst expectations. A pattern of consistent beats signals strong management execution; repeated misses may indicate structural challenges. Analyst EPS estimates are formed from a combination of forward guidance, sector trends, and macroeconomic inputs.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2026-02-05	2025-12-31	0.9	0.95	0.05	5
2025-11-06	2025-09-30	1.11	1.27	0.16	14
2025-08-07	2025-06-30	1.02	1.1	0.08	7
2025-05-08	2025-03-31	1.22	1.24	0.02	1
2025-02-06	2024-12-31	1.17	1.19	0.02	1
2024-11-07	2024-09-30	1.07	1.12	0.05	4
2024-08-08	2024-06-30	1.01	1.02	0.01	0
2024-05-09	2024-03-31	0.89	0.9	0.01	1
2024-02-08	2023-12-31	0.94	1.04	0.1	10
2023-11-02	2023-09-30	0.89	0.99	0.1	11
2023-08-08	2023-06-30	0.73	1.05	0.32	43
2023-05-11	2023-03-31	0.7	0.77	0.07	10
2023-02-07	2022-12-31	0.82	0.85	0.03	3
2022-11-07	2022-09-30	0.67	0.83	0.16	23
2022-08-10	2022-06-30	0.51	0.58	0.07	13
2022-05-10	2022-03-31	0.6	0.65	0.05	8
2022-02-08	2021-12-31	0.73	0.84	0.11	15
2021-11-09	2021-09-30	0.61	0.6	-0.01	1
2021-08-11	2021-06-30	0.45	0.5	0.05	11
2021-05-13	2021-03-31	0.67	0.46	-0.21	31
2021-02-02	2020-12-31	0.65	0.81	0.16	24
2020-11-04	2020-09-30	0.51	0.62	0.11	21
2020-08-04	2020-06-30	0.41	0.46	0.05	12
2020-05-05	2020-03-31	0.73	0.69	-0.04	5
2020-02-04	2019-12-31	0.76	0.94	0.18	23
2019-11-01	2019-09-30	0.72	0.87	0.15	20
2019-08-06	2019-06-30	0.64	0.81	0.17	26
2019-05-07	2019-03-31	0.55	0.61	0.06	10
2019-02-05	2018-12-31	0.59	0.63	0.04	6
2018-11-06	2018-09-30	0.54	0.56	0.02	3
2018-08-07	2018-06-30	0.42	0.59	0.17	40
2018-05-08	2018-03-31	0.43	0.43	0.0	0
2018-02-06	2017-12-31	0.44	0.62	0.18	40
2017-11-07	2017-09-30	0.41	0.48	0.07	17
2017-08-07	2017-06-30	0.3	0.33	0.03	10
2017-05-08	2017-03-31	0.38	0.39	0.01	2
2017-02-06	2016-12-31	0.4	0.43	0.03	7
2016-11-07	2016-09-30	0.35	0.46	0.11	31
2016-08-01	2016-06-30	0.29	0.25	-0.04	13
2016-05-02	2016-03-31	0.46	0.37	-0.09	19
2016-02-01	2015-12-31	0.45	0.48	0.03	6
2015-11-04	2015-09-30	0.4	0.44	0.04	10
2015-07-27	2015-06-30	0.31	0.35	0.04	12
2015-04-27	2015-03-31	0.52	0.47	-0.05	9
2015-01-29	2014-12-31	0.51	0.53	0.02	3
2014-11-03	2014-09-30	0.45	0.47	0.02	4
2014-07-30	2014-06-30	0.35	0.38	0.03	8
2014-04-28	2014-03-31	0.58	0.46	-0.12	20
2014-01-27	2013-12-31	0.6	0.61	0.01	1
2013-10-28	2013-09-30	0.55	0.66	0.11	20
2013-07-29	2013-06-30	0.39	0.46	0.07	17
2013-05-01	2013-03-31	0.46	0.48	0.02	4
2013-01-30	2012-12-31	0.48	0.5	0.02	4
2012-10-29	2012-09-30	0.39	0.45	0.06	15
2012-08-01	2012-06-30	0.35	0.28	-0.07	20
2012-04-29	2012-03-31	0.42	0.4	-0.02	4
2012-01-30	2011-12-31	0.4	0.43	0.03	7
2011-10-31	2011-09-30	0.39	0.36	-0.03	7
2011-08-01	2011-06-30	0.39	0.33	-0.06	15
2011-05-02	2011-03-31	0.42	0.43	0.01	2
2011-01-31	2010-12-31	0.41	0.45	0.04	9
2010-11-01	2010-09-30	0.38	0.4	0.02	5
2010-08-02	2010-06-30	0.36	0.37	0.01	2
2010-05-04	2010-03-31	0.38	0.38	0.0	0
2010-02-01	2009-12-31	0.36	0.36	0.0	0
2009-11-02	2009-09-30	0.32	0.35	0.03	9
2009-08-03	2009-06-30	0.33	0.35	0.02	6
2009-05-04	2009-03-31	0.32	0.33	0.01	3
2009-02-02	2008-12-31	0.3	0.32	0.02	6
2008-10-27	2008-09-30	0.26	0.29	0.03	11
2008-08-01	2008-06-30	0.27	0.3	0.03	11
2008-05-01	2008-03-31	0.29	0.29	0.0	0
2008-01-31	2007-12-31	0.27	0.28	0.01	3
2007-11-01	2007-09-30	0.23	0.23	0.0	0
2007-08-02	2007-06-30	0.25	0.25	0.0	0
2007-05-02	2007-03-31	0.26	0.36	0.1	38
2007-01-31	2006-12-31	0.24	0.25	0.01	4
2006-10-31	2006-09-30	0.22	0.2	-0.02	9
2006-07-27	2006-06-30	0.25	0.22	-0.03	12
2006-05-03	2006-03-31	0.28	0.31	0.03	10
2006-01-30	2005-12-31	0.23	0.25	0.02	8
2005-10-27	2005-09-30	0.19	0.2	0.01	5
2005-07-28	2005-06-30	0.19	0.24	0.05	26
2005-05-05	2005-03-31	0.18	0.19	0.01	5
2005-01-31	2004-12-31	0.18	0.23	0.05	27
2004-11-01	2004-09-30	0.17	0.17	0.0	0
2004-07-29	2004-06-30	0.19	0.19	0.0	0
2004-05-03	2004-03-31	0.19	0.19	0.0	0
2004-01-22	2003-12-31	0.17	0.19	0.02	11
2003-10-23	2003-09-30	0.14	0.12	-0.02	14
2003-07-24	2003-06-30	0.12	0.11	-0.01	8
2003-04-23	2003-03-31	0.12	0.09	-0.03	25
2003-01-23	2002-12-31	0.17	0.21	0.04	23
2002-10-24	2002-09-30	0.13	0.14	0.01	7
2002-07-24	2002-06-30	0.13	0.13	0.0	0
2002-05-02	2002-03-31	0.14	0.14	0.0	0
2002-01-24	2001-12-31	0.17	0.18	0.01	5
2001-10-25	2001-09-30	0.14	0.19	0.05	35
2001-07-26	2001-06-30	0.15	0.19	0.04	26
2001-05-03	2001-03-31	0.14	0.14	0.0	0
2001-01-25	2000-12-31	0.15	0.17	0.02	13
2000-10-26	2000-09-30	0.14	0.13	-0.01	7
2000-07-27	2000-06-30	0.13	0.13	0.0	0
2000-05-04	2000-03-31	0.14	0.14	0.0	0
2000-01-27	1999-12-31	0.13	0.13	0.0	0
1999-10-28	1999-09-30	0.1	0.11	0.01	10
1999-07-29	1999-06-30	0.09	0.11	0.02	22
1999-05-06	1999-03-31	0.09	0.12	0.03	33
1999-01-29	1998-12-31	0.1	0.09	-0.01	10
1998-10-26	1998-09-30	0.08	0.1	0.02	25
1998-07-27	1998-06-30	0.08	0.1	0.02	25
1998-05-04	1998-03-31	0.11	-0.06	-0.17	154
1998-01-27	1997-12-31	0.11	0.09	-0.02	18
1997-10-16	1997-09-30	0.11	0.08	-0.03	27
1997-04-15	1997-03-31	0.13	0.14	0.01	7
1997-01-14	1996-12-31	0.13	0.13	0.0	0
1996-10-11	1996-09-30	0.17	0.16	-0.01	5
1996-07-15	1996-06-30	0.16	0.17	0.01	6
1996-04-18	1996-03-31	0.17	0.17	0.0	0
1996-01-15	1995-12-31	0.16	0.16	0.0	0
1995-10-15	1995-09-30	0.16	0.17	0.01	6
1995-07-16	1995-06-30	0.16	0.16	0.0	0

Use Haemonetics in pair-trading

A pair strategy built around Haemonetics is useful when investors want to reduce directional market exposure while still expressing a relative-value idea. A disciplined pair strategy still requires monitoring because correlation can weaken when market regimes change.

Haemonetics Pair Trading

Haemonetics Pair Trading Analysis

The ability to find closely correlated positions to Haemonetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Haemonetics when you sell it.

The correlation of Haemonetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.

Use Correlation analysis and pair trading evaluation for Haemonetics to review hedging context. The method can be applied across sectors and broader equity sets.

Pair Correlation Correlation Matching

Use Investing Themes to Complement your Haemonetics position

Haemonetics Healthcare sector classification and 2.79 Billion smaller-cap scale make it a natural anchor for themes targeting Medical Instruments & Supplies exposure. Haemonetics 2.79 Billion smaller-cap footprint in Medical Instruments & Supplies aligns sector exposure with portfolio construction goals rather than adding an isolated Healthcare position.

Did You Try This Idea?

Run Large & Mid Caps ETFs Thematic Idea Now

Large & Mid Caps ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 95 constituents at this time.

Investors can hold the Large & Mid Caps ETFs Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.

View All Next

Launch

More Resources for Haemonetics Stock Analysis

A structured review of Haemonetics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Haemonetics Stock. Outlined below are key reports that provide context for Haemonetics Stock:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

	Number Of Shares Shorted vs Return On Equity
	Return On Asset vs Net Income
	Number Of Shares Shorted vs Profit Margin
	Operating Margin vs Net Income
	Number Of Shares Shorted vs Current Valuation
	Shares Outstanding vs Net Income
	Number Of Shares Shorted vs Shares Owned By Insiders
	Shares Owned By Institutions vs Net Income
	Number Of Shares Shorted vs Price To Earning
	Price To Book vs Net Income
	Number Of Shares Shorted vs Price To Sales
	Revenue vs Net Income
	Number Of Shares Shorted vs Gross Profit
	EBITDA vs Net Income
	Number Of Shares Shorted vs Cash And Equivalents

Haemonetics Number Of Shares Shorted vs. Net Income

Revenue by Earning Segment

Haemonetics Revenue by Earnings Segment Overview

Haemonetics Net Income vs. Number Of Shares Shorted Fundamental Analysis

Haemonetics Net Income vs. Number Of Shares Shorted

Haemonetics

Shares Shorted

by Public

+

by Institutions

Haemonetics

Net Income

(Rev + Gain)

-

(Exp + Loss)

Haemonetics Net Income Comparison

Haemonetics Profitability Projections

Haemonetics Profitability Driver Comparison

Earnings Estimation Breakdown

Earnings Projection Consensus

Earnings History

Haemonetics Quarterly Gross Profit

Earnings per Share Projection vs Actual

Estimated Months Earnings per Share

Quarterly Analyst Estimates and Surprise Metrics

Use Haemonetics in pair-trading

Haemonetics Pair Trading

Haemonetics Pair Trading Analysis

Use Investing Themes to Complement your Haemonetics position

Did You Try This Idea?

Run Large & Mid Caps ETFs Thematic Idea Now

Large & Mid Caps ETFs

More Resources for Haemonetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY